Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Rate of normalization of VEGF defined as VEGF value decreasing to below upper limit of normal (86 pg/mL)
研究概览
简要总结
This phase II trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work in treating patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving ixazomib citrate, lenalidomide, and dexamethasone may work better in treating patients with POEMS syndrome.
详细描述
PRIMARY OBJECTIVE:
I. Normalization of VEGF after 3 cycles of therapy.
SECONDARY OBJECTIVES:
I. Toxicity and safety of the combination of ixazomib citrate (ixazomib), lenalidomide, and dexamethasone.
II. Hematologic response after 3 cycles of therapy. III. Hematologic response rates and/or VEGF response at 12 months. IV. Overall survival.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •POEMS syndrome requiring therapy, previously treated or untreated
- •Plasma vascular endothelial growth factor (VEGF) > 2 x upper limit of normal (ULN)
- •Presence of a plasma cell clone (any of the following):
- •Monoclonal protein in the serum or urine
- •Measurable light chains by free light chain assay
- •Measurable plasmacytoma
- •Monoclonal plasma cells in bone marrow
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2, or 3
- •Absolute neutrophil count (ANC) >= 1000/uL obtained =< 14 days prior to registration
- •Platelet count (PLT) >= 75,000/uL obtained =< 14 days prior to registration
- •Total bilirubin =< 2.0 mg/dL unless due to known Gilbert's disease obtained =< 14 days prior to registration
- •NOTE: If total bilirubin is > 2 mg/dL, a direct bilirubin should be performed and must be < 1.5 mg/dL for Gilbert's to be diagnosed
- •Alanine aminotransferase (ALT/serum glutamic pyruvic transaminase [SGPT]) and aspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x upper limit of normal (ULN) obtained =< 14 days prior to registration
- •Creatinine clearance >= 30 mL/min/1.73 m^2 (as determined by Cockcroft-Gault equation) obtained =< 14 days prior to registration
- •Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- •NOTE: Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid Risk Evaluation and Mitigation Strategy (REMS) program
- •Birth control
- •Female patients of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication
- •NOTE: Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
- •Male patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy
- •NOTE: Abstinence is acceptable (for either males or females) if this is the established and preferred method of contraception for the subject
- •Willing to adhere to the guidelines of the Revlimid REMS (formerly known as RevAssist) program
- •NOTE: The counseling must be documented
- •Provide written informed consent
- •Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- •Note: During the active monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
- •No contraindication to be on a minimum of 81 mg aspirin a day (or other anticoagulant therapy as prescribed) for thromboembolism prophylaxis
- •Willing to provide mandatory blood and bone marrow samples for research purposes
- •Ability to complete questionnaire(s) by themselves or with assistance
排除标准
- •Recent prior chemotherapy:
- •Newly diagnosed patients (regardless of group); any prior chemotherapy for POEMS with the following exceptions:
- •Prior immunomodulators like azathioprine, cyclosporin, and/or corticosteroids are not exclusionary therapies if used for prior diagnosis of chronic inflammatory demyelinating polyneuropathy
- •Prior chemotherapy directed at a "myeloproliferative neoplasm" like hydroxyurea is not exclusionary
- •Previously treated patients (group 2)
- •Alkylators (e.g. melphalan, cyclophosphamide) =< 28 days prior to registration
- •Anthracyclines =< 28 days prior to registration
- •High dose corticosteroids, immune modulatory drugs (thalidomide or lenalidomide), or proteosome inhibitors (e.g. ixazomib or bortezomib) =< 28 days prior to registration
- •Requirement for concomitant high dose corticosteroids
- •EXCEPTION: Patients may be on chronic steroids (maximum dose 20 mg/day prednisone equivalent) if they are being given for adrenal insufficiency, rheumatoid arthritis, etc
- •Receiving any other investigational agent, which would be considered as a treatment for the primary neoplasm
- •Participation in other clinical trials, including those with other investigational agents not included in this trial, =< 30 days prior to registration and throughout the duration of this trial
- •Prior refractoriness to proteasome inhibitor or immunomodulatory drugs (IMiD)
- •Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
- •Pregnant women
- •Nursing women
- •Men or women of childbearing potential who are unwilling to employ adequate contraception
- •Other active malignancy =< 3 years prior to registration
- •EXCEPTIONS: Non-melanotic skin cancer, ductal carcinoma in-situ, or carcinoma-in-situ of the cervix
- •NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
- •Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens, e.g. uncontrolled infection (infection requiring systemic antibiotic therapy or other serious infection =< 14 days prior to registration); or uncompensated heart or lung disease
- •Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy
- •Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of St. John's wort =< 14 days prior to registration
- •History of myocardial infarction =< 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
- •Radiotherapy =< 14 days prior to registration
- •Major surgery =< 14 days prior to registration
- •Failure to fully recover (i.e. =< grade 1 adverse event [AE]) from the reversible effects of prior chemotherapy
- •Known allergy to any of the study medications, their analogs, or excipients in the various formulations of any agent
- •Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of the study drugs including difficulty swallowing
- •Ongoing or active systemic infection or active hepatitis B or C virus infection
研究组 & 干预措施
Group I (ixazomib citrate, lenalidomide, dexamethasone, ASCT)
Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 cycles of treatment.
干预措施: Dexamethasone (Drug)
Group I (ixazomib citrate, lenalidomide, dexamethasone, ASCT)
Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 cycles of treatment.
干预措施: Ixazomib Citrate (Drug)
Group I (ixazomib citrate, lenalidomide, dexamethasone, ASCT)
Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 cycles of treatment.
干预措施: Lenalidomide (Drug)
Group I (ixazomib citrate, lenalidomide, dexamethasone, ASCT)
Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo standard of care ASCT after completing 3 cycles of treatment.
干预措施: Questionnaire Administration (Other)
Group II (ixazomib citrate, lenalidomide, dexamethasone)
Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
干预措施: Dexamethasone (Drug)
Group II (ixazomib citrate, lenalidomide, dexamethasone)
Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
干预措施: Ixazomib Citrate (Drug)
Group II (ixazomib citrate, lenalidomide, dexamethasone)
Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
干预措施: Lenalidomide (Drug)
Group II (ixazomib citrate, lenalidomide, dexamethasone)
Patients receive ixazomib citrate PO, lenalidomide PO QD, and dexamethasone PO as in Group I. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
干预措施: Questionnaire Administration (Other)
结局指标
主要结局
Rate of normalization of VEGF defined as VEGF value decreasing to below upper limit of normal (86 pg/mL)
时间窗: Up to 3 months
In each group, the rate of normalization of VEGF by 3 months (post-3 cycles) will be examined along with the prognostic factors for patients accrued to this study. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Ninety-five percent binomial confidence intervals for the true success proportion will be calculated.
次要结局
- Normalization of VEGF(Up to 12 months)
- Incidence of adverse events evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0(Up to 3 years)
- Hematologic response rate(Up to 12 months)
- Survival time(Time from registration to death due to any cause, assessed up to 3 years)